SMM also shows an M protein on SPEP and is similar to MGUS in its lack of clinical manifestations but is more likely to progress to symptomaticmyeloma; progression to MM is 10% per year for the first 5 years, 3% per year for the subsequent 5 years, and 2% per year for the 5 years...
"What this new work shows us is that when we treat an individual patient withmultiple myeloma, it's possible that we're not just looking at one disease, but at many – in the same person, there could becancer cellswith different genetic make-ups," said co-senior author Todd Golub, the...
In patients with lens-refractory multiple myeloma, cilta-cel generated deeper minimal residual disease rates across all patient subgroups. Reduction in AEs by Pelabresib With Ruxolitinib in JAK-Naive Myelofibrosis Jonah Feldman December 11th 2024 ...
tumor heterogeneity, tumor microenvironment, therapeutic resistance in MM, which offers a profound opportunity to improve the diagnosis and identify biomarkers for precision medicine of MM. SCS: single-cell sequencing; MM: multiple myeloma; MGUS: monoclonal...
Multiple myeloma was initially termed “multiple” to distinguish it from plasmacytoma, a solitary tumor of a bone or an organ/tissue. Solitary plasmacytoma (SP) may develop further into a solitary plasmacytoma with minimal marrow involvement (SPMMI). Both SP and SPMMI are characterized by monoclo...
Multiple myeloma is a currently incurable malignancy of terminally differentiated plasma cells. It typically occurs in older patients (median age 71 years). Clinical manifestations result from monocl...
Cosmeri Rizzato (DKFZ, Heidelberg, Germany) for assistance with lab work. Int. J. Cancer: 00, 00–00 (2014) VC 2014 UICC 8 Telomerase SNPs, telomere length and myeloma risk References 1. Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet 2009;374:324–39. 2. Martino...
The requirement for bone-marrow aspirates for genomic profiling of multiple myeloma poses an obstacle to enrolment and retention of patients in clinical trials. We evaluated whether circulating cell-free DNA (cfDNA) analysis is comparable to molecular pr
Activation of CD28 on multiple myeloma (MM) plasma cells, by binding to CD80 and CD86 on dendritic cells, decreases proteasome subunit expression in the tumor cells and thereby helps them evade being killed by CD8+ T cells. Understanding how CD28 activat
Education Lab | CME | This monograph discusses new agents that are being introduced for relapsed/refractory multiple myeloma and the role these agents are likely to play when they become commercially available in the United States. Optimal induction therapy is also reviewe...